Generic drug maker Actavis has agreed to pay $5 billion in stock and assumed $3.5 billion in debt to acquire Irish rival Warner Chilcott. The deal comes less than a month after the collapse of a tentative deal that would have seen Actavis sold to Valeant Pharmaceuticals for $13 billion.
Latham, Davis Polk Lead as Actavis Buys Generic Rival
The Am Law Daily
May 20, 2013
This content is now available at LexisNexis®.
The ALM® and LexisNexis® Content Alliance
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM’s legal news publications. LexisNexis® customers will be able to access and use ALM’s content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM’s other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM’s content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
If you are not currently a LexisNexis subscriber, contact 1-800-227-4908 to find out more or click here to have a customer representative contact you directly.